Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Visterra publishes preclinical dengue data
September 2015
by  |  Email the author
EDIT CONNECT

SHARING OPTIONS:

CAMBRIDGE, Mass.—New preclinical results for VIS520, Visterra Inc.’s novel monoclonal antibody being developed as a treatment for dengue, were published mid-July in Cell, the company announced. The preclinical work united scientists from Visterra, MIT, Duke-National University of Singapore, the Singapore-MIT Alliance for Research and Technology Center and Nanyang Technological University, and demonstrated that VIS513 binds and potentially neutralizes all four serotypes of dengue virus, serving to protect mice challenged with a lethal dose of the virus.
 
Dr. Zach Shriver, Visterra’s vice president of research, remarked, “We are very encouraged by the ability of a single administration of VIS513 to rapidly reduce and virtually eliminate viremia and mitigate symptoms of severe dengue infection in multiple mouse models. These new preclinical data further demonstrate the potential of VIS513 to effectively neutralize across all four dengue virus serotypes and provide additional support for Visterra’s plans to advance VIS513 into clinical development.”
 
Code:

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.